India's largest drug maker Sun Pharma announced today it commenced rollout of InfuSMART, what it claimed is the world's first ready-to-administer versions of anti-cancer drug gemcitabine in six European countries including Netherlands, UK, Spain, Germany, Italy and France.
The company said the product that will be available in a bag, is part of its business strategy to build a "meaningful and differentiating presence in the global oncology therapy market." Gemcitabine is indicated in the treatment of ovarian, lung, breast and pancreatic cancer. Sun Pharma hinted at more oncology products being developed on the same lines.
The company said the product that will be available in a bag, is part of its business strategy to build a "meaningful and differentiating presence in the global oncology therapy market." Gemcitabine is indicated in the treatment of ovarian, lung, breast and pancreatic cancer. Sun Pharma hinted at more oncology products being developed on the same lines.
With sales of $4.3 billion for FY 2016, Sun Pharma is accelerating its efforts to build a global branded products business and has identified areas where it feels considerable need gaps exist. It said InfuSMART is expected to play an increasing role due to improved safety, convenience and time saving benefits.
Industry estimates suggest the annual requirement for such products in Europe could be to the tune of 13 to 15 million units for the top 35 products delivered as intravenous fluids. Sun said its product was developed by its scientists based in India.
Industry estimates suggest the annual requirement for such products in Europe could be to the tune of 13 to 15 million units for the top 35 products delivered as intravenous fluids. Sun said its product was developed by its scientists based in India.
Sun added it has received regulatory approval to sell gemcitabine InfuSMART in eight key stock keeping units. The concept involved dose banding practice whereby, through agreement between prescribers and pharmacists, standardized doses of intravenous cytotoxic drugs are used for ranges of doses calculated for individual patients.
While traditionally such medicines are compounded at hospitals or outsourced to compounding pharmacies taking a longer time to process, Hellen de Kloet, Sun Pharma's business head of western Europe and ANZ noted InfuSMART will provide differentiating solutions.
The UK National Health Service has been encouraging development of licensed RTA products and has issued guidelines for procuring such products. Large drug makers like Mylan, Fresenius, Hospira and Baxter are among the companies that have indicated interest in ready-to-administer products.
As many as 14 million new cases of cancer was detected in 2012 while 8.2 million died during 2012, data from WHO showed. Cancer cases are expected to rise by about 70% over the next two decades.
As many as 14 million new cases of cancer was detected in 2012 while 8.2 million died during 2012, data from WHO showed. Cancer cases are expected to rise by about 70% over the next two decades.
No comments:
Post a Comment